VRDN Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

15.75M

+21775.19%

-0.985

+21.66%

14.29K

-80.15%

-1.077

+23.85%

12.62M

+16728.57%

-1.012

+1.25%

Estimates Revision

The market is revising Upward the revenue expectations for Viridian Therapeutics, Inc. (VRDN) for FY2025, with the revenue forecasts being adjusted by 476.42% over the past three months. During the same period, the stock price has changed by 45.58%.

Revenue Estimates for FY2025

Revise Upward

+476.42%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-13.45%

In Past 3 Month

Stock Price

Go Up

+45.58%

In Past 3 Month

13 Analyst Rating

Wall Street analysts forecast VRDN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VRDN is 39.73 USD with a low forecast of 14.02 USD and a high forecast of 61.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

13 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

14.02

Averages

39.73

High

61.00

Current: 0.000

Low

14.02

Averages

39.73

High

61.00

UBS

Buy

initiated

$50

2026-01-07

New

Reason

UBS

Price Target

$50

2026-01-07

New

initiated

Buy

Reason

UBS initiated coverage of Viridian Therapeutics (VRDN) with a Buy rating and $50 price target as the analyst initiated or assumed coverage on 22 small-to-mid cap biotech names. After a rough period, biotech fundamentals are now inflecting, contends the analyst, who expects investor confidence to recover and sees this positioning biotech for strong performance in 2026. Among the group, top picks include Apogee Therapeutics (APGE), Cogent Biosciences (COGT), Kodiak Sciences (KOD), Ideaya Biosciences (IDYA), Inventiva (IVA), SAB Biotherapeutics (SABS) and Ventyx Biosciences (VTYX), which the analyst highlights as having key upcoming catalysts, de-risked best-in-class portfolios, strong data, and broader pipelines.

William Blair

Outperform

initiated

$47

2025-12-03

Reason

William Blair

Price Target

$47

2025-12-03

initiated

Outperform

Reason

William Blair initiated coverage of Viridian Therapeutics with an Outperform rating and $47 fair value estimate. The firm believes the company's anti-IGF-1R franchise represents a "meaningful advance" compared to Tepezza for the treatment of thyroid eye disease. While growth in the U.S. TED market has plateaued in recent years, new therapies have potential to grow the market, the analyst tells investors in a research note. Blair believes Viridian's veligrotug has important advantages over Tepezza that could drive market share capture.

Truist

NULL

Buy

initiated

$41

2025-11-24

Reason

Truist

Price Target

$41

2025-11-24

initiated

NULL

Buy

Reason

Truist initiated coverage of Viridian Therapeutics with a Buy rating and $41 price target. The firm, which thinks Viridian is well-positioned following veligrotug's BLA submission and potential launch in thyroid eye disease, notes that its valuation is driven by veligrotug.

Goldman Sachs

Buy

maintain

$30 -> $40

2025-11-06

Reason

Goldman Sachs

Price Target

$30 -> $40

2025-11-06

maintain

Buy

Reason

Goldman Sachs raised the firm's price target on Viridian Therapeutics to $40 from $30 and keeps a Buy rating on the shares.

RBC Capital

Outperform

maintain

$41 -> $45

2025-11-06

Reason

RBC Capital

Price Target

$41 -> $45

2025-11-06

maintain

Outperform

Reason

RBC Capital raised the firm's price target on Viridian Therapeutics to $45 from $41 and keeps an Outperform rating on the shares following the Q3 report. Despite the government shutdown, the company submitted the applicatoin for veligrotug in late October, the analyst tells investors in a research note. The firm thinks the drug offers "meaningful differentiation" from the standard-of-care Tepezza and is highly likely to gain approval.

Oppenheimer

Outperform

maintain

$32 -> $36

2025-10-21

Reason

Oppenheimer

Price Target

$32 -> $36

2025-10-21

maintain

Outperform

Reason

Oppenheimer raised the firm's price target on Viridian Therapeutics to $36 from $32 and keeps an Outperform rating on the shares. The firm believes the recent royalty financing - which could well enable Viridian to achieve profitability without further equity dilution - sets a firm capital foundation as the company nears commercial entry into the $2B annual U.S. thyroid eye disease market. Oppenheimer sees shares continuing to run as what it expects to be a series of positive events transpires: IV veligrotug's BLA submission in the coming weeks and subcutaneous VRDN-003's Phase 3 readouts in the first half of 2026.

Valuation Metrics

The current forward P/E ratio for Viridian Therapeutics Inc (VRDN.O) is -7.66, compared to its 5-year average forward P/E of -4.77. For a more detailed relative valuation and DCF analysis to assess Viridian Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-4.77

Current PE

-7.66

Overvalued PE

-3.44

Undervalued PE

-6.10

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-3.81

Current EV/EBITDA

-7.66

Overvalued EV/EBITDA

-1.88

Undervalued EV/EBITDA

-5.75

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

2443.65

Current PS

62.53

Overvalued PS

5035.82

Undervalued PS

-148.53

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

VRDN News & Events

Events Timeline

No data

News

8.5

2025-12-31Benzinga

Biotech Stocks Surge in 2025 with $30.9 Billion M&A Wave

9.0

2025-12-23NASDAQ.COM

Viridian Therapeutics (VRDN) Secures FDA Priority Review for Veligrotug in Thyroid Eye Disease

9.0

2025-12-15Benzinga

Argenx Suspends Phase 3 Trial for Thyroid Eye Disease, Opening Opportunities for Competitors Like Viridian Therapeutics

People Also Watch

Frequently Asked Questions

What is Viridian Therapeutics Inc (VRDN) stock price today?

The current price of VRDN is 31.75 USD — it has increased 4.68 % in the last trading day.

What is Viridian Therapeutics Inc (VRDN)'s business?

Viridian Therapeutics, Inc. is a biopharmaceutical company focused on engineering and developing potential medicines for patients with serious and rare diseases. The Company is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The Company is conducting two global Phase 3 clinical trials (THRIVE and THRIVE-2) to evaluate the safety and efficacy of veligrotug in patients with active and chronic TED. It is also conducting two global Phase 3 clinical trials, REVEAL-1 and REVEAL-2, to evaluate the efficacy and safety of VRDN-003 in patients. Its advanced program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED. In addition to its TED portfolio, the Company is advancing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors, including VRDN-006 and VRDN-008, which has the potential to be developed in multiple autoimmune diseases.

What is the price predicton of VRDN Stock?

What is Viridian Therapeutics Inc (VRDN)'s revenue for the last quarter?

Viridian Therapeutics Inc revenue for the last quarter amounts to 70.57M USD, increased 81958.14 % YoY.

What is Viridian Therapeutics Inc (VRDN)'s earnings per share (EPS) for the last quarter?

Viridian Therapeutics Inc. EPS for the last quarter amounts to -0.42 USD, decreased -63.48 % YoY.

What changes have occurred in the market's expectations for Viridian Therapeutics Inc (VRDN)'s fundamentals?

How many employees does Viridian Therapeutics Inc (VRDN). have?

Viridian Therapeutics Inc (VRDN) has 143 emplpoyees as of January 10 2026.

What is Viridian Therapeutics Inc (VRDN) market cap?

Today VRDN has the market capitalization of 3.03B USD.